Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs LY 3154207 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Eli Lilly
- 20 Mar 2017 Status changed from active, no longer recruiting to completed.
- 24 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Feb 2017.
- 24 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2017.